{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:06:26Z","timestamp":1791241586871,"version":"4.1.0"},"reference-count":93,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Geneva"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The management of chemotherapy-induced nausea and vomiting (CINV) in children remains challenging due to differences in the chemotherapy regimens, their relative emetogenicity compared to that in adults and differences in drug metabolism and the available formulations. The common four classes of anti-emetics used for the treatment and prophylaxis of CINV in children include dexamethasone, neurokinin-1 receptor antagonists, 5-hydroxytryptamine-3 receptor antagonists (5HT3RAs), and olanzapine. The appropriate dose of dexamethasone for CINV prophylaxis in children is unknown, with a significant variability in dosage ranging between 6 and 32 mg\/m2\/day. The dose of dexamethasone is decreased by 30% when this drug is combined with (fos)aprepitant in children, in contrast to a decrease of 50% required in adults. The use of aprepitant in younger children (&lt;12 years) is often hampered by the non-availability of oral suspension formulations in many countries; alternatively, 80 mg capsules are administered for 1\u20133 days in certain institutes to children weighing between 15 and 40 kg. Among the different 5HT3RAs, palonosetron is comparatively metabolized faster in children than in adults, requiring a higher dosage for similar efficacy to that achieved in adults. Olanzapine is a newer agent, used in doses between 0.1 and 0.14 mg\/kg\/day in children, with good anti-emetic efficacy, but has sedation and hyperglycemia as concerning adverse effects. Drug interactions between anti-emetics and between anti-emetics and chemotherapy\/supportive agents (azole antifungals, cyclosporine, arsenic trioxide), especially QTc prolongation, should be considered during prescription.<\/jats:p>","DOI":"10.3390\/ph17050616","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T08:59:37Z","timestamp":1715677177000},"page":"616","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anti-Emetics in Children Receiving Chemotherapy for Solid Tumors and Leukemia: Pharmacology and Optimization of Therapy for Nausea and Vomiting"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7296-6088","authenticated-orcid":false,"given":"Shuvadeep","family":"Ganguly","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Sasi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh Kumar Kodagalli","family":"Nagaraju","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.phoj.2023.07.003","article-title":"Assessment of chemotherapy-induced nausea and vomiting in pediatrics: Adequacy of control and adherence to guidelines","volume":"8","author":"Awwad","year":"2023","journal-title":"Pediatr. Hematol. Oncol. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00520-016-3384-y","article-title":"2016 updated MASCC\/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children","volume":"25","author":"Dupuis","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1177\/0300060518765324","article-title":"Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment","volume":"46","author":"Ruggiero","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e30001","DOI":"10.1002\/pbc.30001","article-title":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline","volume":"69","author":"Patel","year":"2022","journal-title":"Pediatr. Blood Cancer."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/jcph.1577","article-title":"Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting","volume":"60","author":"Momper","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.20.00134","article-title":"Factors Associated With Chemotherapy-Induced Vomiting Control in Pediatric Patients Receiving Moderately or Highly Emetogenic Chemotherapy: A Pooled Analysis","volume":"38","author":"Dupuis","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1177\/10781552221122026","article-title":"Risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy","volume":"29","author":"Eliasen","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/pbc.25108","article-title":"Predictors of antiemetic alteration in pediatric acute myeloid leukemia","volume":"61","author":"Freedman","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fphar.2020.00329","article-title":"Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review","volume":"11","author":"Mosa","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2217\/pgs.10.67","article-title":"Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy","volume":"11","author":"Hammer","year":"2010","journal-title":"Pharmacogenomics."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/1099800412449181","article-title":"The association of CYP2D6 genotype and postoperative nausea and vomiting in orthopedic trauma patients","volume":"15","author":"Wesmiller","year":"2013","journal-title":"Biol. Res. Nurs."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/cts.13447","article-title":"Pediatric CYP2D6 metabolizer status and post-tonsillectomy nausea and vomiting after ondansetron","volume":"16","author":"Black","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13023-023-02770-x","article-title":"Aspartame and Phenylketonuria: An analysis of the daily phenylalanine intake of aspartame-containing drugs marketed in France","volume":"18","author":"Maler","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00280-013-2201-2","article-title":"Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids","volume":"72","author":"Sun","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/00185787221074563","article-title":"Compatibility and Physical Properties of Dexamethasone-Ondansetron Intravenous Admixture","volume":"57","author":"Suknuntha","year":"2022","journal-title":"Hosp. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e28716","DOI":"10.1002\/pbc.28716","article-title":"Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review","volume":"67","author":"Patel","year":"2020","journal-title":"Pediatr. Blood Cancer."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1007\/s00520-022-07423-6","article-title":"Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting","volume":"30","author":"Nijstad","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1002\/cam4.2486","article-title":"Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database","volume":"8","author":"Bun","year":"2019","journal-title":"Cancer Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e27488","DOI":"10.1002\/pbc.27488","article-title":"Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals","volume":"66","author":"McKinnon","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: A randomised, double-blind, phase 3 trial","volume":"16","author":"Kang","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1007\/s00520-015-2714-9","article-title":"Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: A randomized, double-blind, placebo-controlled trial","volume":"23","author":"Bakhshi","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_23","first-page":"3","article-title":"Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications","volume":"63","author":"Keck","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Willier, S., Stanchi, K.M.C., von Have, M., Binder, V., Blaeschke, F., Feucht, J., Feuchtinger, T., and D\u00f6ring, M. (2019). Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy\u2014Results of a non-interventional observation study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6252-6"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1586\/14737140.8.11.1733","article-title":"Fosaprepitant: A neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting","volume":"8","author":"Navari","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e27690","DOI":"10.1002\/pbc.27690","article-title":"Pharmacokinetics\/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients","volume":"66","author":"Mora","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/pbc.25286","article-title":"Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: A retrospective, multi-center review","volume":"62","author":"Flank","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"705866","DOI":"10.3389\/fonc.2021.705866","article-title":"The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MPH.0000000000001357","article-title":"Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial","volume":"41","author":"Chaudhary","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e28947","DOI":"10.1002\/pbc.28947","article-title":"Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update","volume":"68","author":"Patel","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/08880010590896468","article-title":"A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer","volume":"22","author":"Sarper","year":"2005","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00003088-199529020-00004","article-title":"Ondansetron clinical pharmacokinetics","volume":"29","author":"Roila","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0959-8049(99)00071-4","article-title":"A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy","volume":"35","author":"Komada","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"ref_34","first-page":"259","article-title":"Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: Double-blind study of 2 doses","volume":"87","author":"Mabro","year":"2000","journal-title":"Bull. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/jjco\/29.2.92","article-title":"Tropisetron (Navoban) in the control of nausea and vomiting induced by combined cancer chemotherapy in children","volume":"29","author":"Ozkan","year":"1999","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9570","DOI":"10.1200\/jco.2007.25.18_suppl.9570","article-title":"Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: A multicenter, stratified, double-blind, phase 3, randomized study","volume":"25","author":"Kadota","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.6004\/jnccn.2007.0005","article-title":"Are all 5-HT3 receptor antagonists the same?","volume":"5","author":"McNulty","year":"2007","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2013.10.008","article-title":"The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting","volume":"722","author":"Chu","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/cpt1975182205","article-title":"Bioavailability of oral dexamethasone","volume":"18","author":"Duggan","year":"1975","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00280-008-0713-y","article-title":"Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting","volume":"63","author":"Nakade","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1007\/s00520-015-2760-3","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin","volume":"23","author":"Furukawa","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1097\/MPH.0000000000001186","article-title":"Safety of Dexamethasone for Nausea and Vomiting Prophylaxis in Children Receiving Hematopoietic Stem Cell Transplantation","volume":"40","author":"Schechter","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00520-021-06472-7","article-title":"Netupitant\/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: A single-center experience","volume":"30","author":"Loteta","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_44","unstructured":"(2024, January 07). FDA Drug Safety Communication: Abnormal Heart Rhythms Associated with Use of Anzemet (Dolasetron Mesylate), Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-abnormal-heart-rhythms-associated-use-anzemet-dolasetron-mesylate."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000087979","article-title":"5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment","volume":"69","author":"Aapro","year":"2005","journal-title":"Oncology."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00003495-199855020-00002","article-title":"5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting","volume":"55","author":"Gregory","year":"1998","journal-title":"Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Tricco, A.C., Blondal, E., Veroniki, A.A., Soobiah, C., Vafaei, A., Ivory, J., Strifler, L., Cardoso, R., Reynen, E., and Nincic, V. (2016). Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: A systematic review and network meta-analysis. BMC Med., 14.","DOI":"10.1186\/s12916-016-0761-9"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"106S","DOI":"10.1016\/S0002-9343(01)00849-X","article-title":"Central neurocircuitry associated with emesis","volume":"111","author":"Hornby","year":"2001","journal-title":"Am. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Nazl\u0131, H., Mesut, B., and \u00d6zsoy, Y. (2021). In Vitro Evaluation of a Solid Supersaturated Self Nanoemulsifying Drug Delivery System (Super-SNEDDS) of Aprepitant for Enhanced Solubility. Pharmaceuticals, 14.","DOI":"10.3390\/ph14111089"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1177\/1078155219828806","article-title":"Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults","volume":"25","author":"Patel","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/0091270005283467","article-title":"Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers","volume":"46","author":"Majumdar","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e27551","DOI":"10.1002\/pbc.27551","article-title":"Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial","volume":"66","author":"Radhakrishnan","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gao, A., Guan, S., Sun, Y., Wang, L., Meng, F., Liu, X., Gu, L., Li, G., Zhong, D., and Zhang, L. (2023). Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11070-3"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"234","DOI":"10.21037\/atm.2019.12.158","article-title":"Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: A multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial","volume":"8","author":"Zhang","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/bcp.13322","article-title":"Aprepitant and fosaprepitant drug interactions: A systematic review","volume":"83","author":"Patel","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/jnci\/djs335","article-title":"Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: A systematic review","volume":"104","author":"Souza","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1136\/bmjspcare-2020-002595","article-title":"Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: A randomised, open-label trial","volume":"13","author":"Sharma","year":"2023","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00520-013-2106-y","article-title":"Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant","volume":"22","author":"Lundberg","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00004714-200004000-00015","article-title":"Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia","volume":"20","author":"Grothe","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/cpdd.765","article-title":"Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions","volume":"9","author":"Fan","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/0091270005283839","article-title":"Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers","volume":"46","author":"Markowitz","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e32116","DOI":"10.1097\/MD.0000000000032116","article-title":"The emerging role of olanzapine in paediatric CINV control: A review","volume":"101","year":"2022","journal-title":"Medicine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.20.00871","article-title":"Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial","volume":"38","author":"Naik","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_64","first-page":"188","article-title":"Prescription of olanzapine in children and adolescent psychiatric patients","volume":"33","author":"Reymann","year":"2007","journal-title":"L\u2019Encephale"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/0269881110370505","article-title":"Weight changes over time in adults treated with the oral or depot formulations of olanzapine: A pooled analysis of 86 clinical trials","volume":"25","author":"Millen","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40264-014-0219-y","article-title":"The safety of olanzapine in young children: A systematic review and meta-analysis","volume":"37","author":"Flank","year":"2014","journal-title":"Drug Saf."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00000421-199504000-00017","article-title":"Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial","volume":"18","author":"Malik","year":"1995","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00520-018-4377-9","article-title":"Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia","volume":"27","author":"Ono","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.5694\/j.1326-5377.1979.tb127271.x","article-title":"Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol","volume":"2","author":"Ekert","year":"1979","journal-title":"Med. J. Aust."},{"key":"ref_70","first-page":"946","article-title":"Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial","volume":"79","author":"Chan","year":"1987","journal-title":"Pediatrics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e27374","DOI":"10.1002\/pbc.27374","article-title":"Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review","volume":"65","author":"Polito","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_72","first-page":"462","article-title":"Characterization of Dronabinol Usage in a Pediatric Oncology Population","volume":"20","author":"Elder","year":"2015","journal-title":"J. Pediatr. Pharmacol Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/pbc.22778","article-title":"Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy","volume":"56","author":"Pillai","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1534735411413266","article-title":"Medicinal plants as antiemetics in the treatment of cancer: A review","volume":"11","author":"Haniadka","year":"2012","journal-title":"Integr. Cancer Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO Guideline Update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J. Clin. Onco.l Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Giagnuolo, G., Buffardi, S., Rossi, F., Petruzziello, F., Tortora, C., Buffardi, I., Marra, N., Beneduce, G., Menna, G., and Parasole, R. (2019). Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215295"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s00520-010-0920-z","article-title":"Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: Review and consensus statement","volume":"19","author":"Einhorn","year":"2011","journal-title":"Support. Care Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e28404","DOI":"10.1002\/pbc.28404","article-title":"Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study","volume":"67","author":"Garg","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e13918","DOI":"10.1111\/petr.13918","article-title":"Allogeneic hematopoietic stem cell transplant in pediatric acute myeloid leukemia: Lessons learnt from a tertiary care center in India","volume":"25","author":"Arora","year":"2021","journal-title":"Pediatr. Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40780-016-0072-5","article-title":"Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: A retrospective cohort study","volume":"3","author":"Itai","year":"2017","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6650915","DOI":"10.1155\/2023\/6650915","article-title":"Pharmacotherapy Considerations in Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. Batra L, editor","volume":"2023","author":"Shahrami","year":"2023","journal-title":"Eur. J. Cancer Care"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e28532","DOI":"10.1002\/pbc.28532","article-title":"Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial","volume":"67","author":"Radhakrishnan","year":"2020","journal-title":"Pediatr. Blood Cancer."},{"key":"ref_83","first-page":"232","article-title":"Chemotherapy-induced nausea and vomiting: Optimizing prevention and management","volume":"5","author":"Rao","year":"2012","journal-title":"Am. Health Drug Benefits"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1200\/JGO.2016.006023","article-title":"Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline","volume":"3","author":"Patil","year":"2017","journal-title":"J. Glob. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/1078155210384301","article-title":"Potential for drug\u2013drug interactions in treating cancer-related nausea and distress","volume":"17","author":"Saylor","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/mnfr.200600300","article-title":"Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John\u2019s wort, and Echinacea","volume":"52","author":"Gurley","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7128909","DOI":"10.1155\/2016\/7128909","article-title":"Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission","volume":"2016","author":"Mazhar","year":"2016","journal-title":"Case Rep. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1592\/phco.26.9.1221","article-title":"Development and Validation of the Pediatric Nausea Assessment Tool for Use in Children Receiving Antineoplastic Agents","volume":"26","author":"Dupuis","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12098-022-04436-1","article-title":"Translation and Psychometric Evaluation of the Hindi Language Version of the Pediatric Nausea Assessment Tool (PeNAT) in the Indian Population","volume":"91","author":"Rasheed","year":"2023","journal-title":"Indian J. Pediatr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/pon.6017","article-title":"Adaptation of the Patient Reported Outcome Measurement Information System (PROMIS) tool for childhood cancer in India: A qualitative study","volume":"31","author":"Sasi","year":"2022","journal-title":"Psychooncology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e1272","DOI":"10.1136\/spcare-2022-004069","article-title":"Olanzapine cost-effectiveness in vomiting and nausea from highly emetogenic chemotherapy in children and adolescents","volume":"13","author":"Sra","year":"2023","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e29795","DOI":"10.1002\/pbc.29795","article-title":"Cost-effectiveness analysis of aprepitant-based anti-emetic regimen for children receiving highly emetogenic chemotherapy: Individual patient data analysis of a randomized trial","volume":"69","author":"Sra","year":"2022","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/5\/616\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:43:32Z","timestamp":1760107412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/5\/616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":93,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ph17050616"],"URL":"https:\/\/doi.org\/10.3390\/ph17050616","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}